

ACG Clinical Guideline: Gastroparesis



Gastroparesis

Definition:

- A syndrome of delayed gastric emptying in the absence of mechanical obstruction with cardinal symptoms including early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain.
- The pathophysiologic mechanisms of gastroparesis are multifactorial, including antroduodenal hypomotility, pylorospasm, impaired gastric accommodation, and visceral hypersensitivity

Epidemiology

Female to male ratio :-

3-4 : I

> Type I diabetics (40%).

Type 2 diabetics (10–20%)

Clinical features:

Chronic nausea and vomiting:

Vomit undigested food up to 4hrs after eating.

Increased frequency and severity in DG.

- **Early satiety**: very full very quickly.
- Post prandial fullness: very full after eating and continue for long time.

Upper abdominal pain:

Vague, burning or crampy.

Worsen with eating.

Nocturnal.

- Bloating or belching.
- Dyspepsia.
- Weight loss.
- Peripheral N. with DM.



A. Idiopathic: Most common cause (IG) 36%.

- No detectable underlying abnormality for the delayed gastric emptying.
- More common in middle aged women.

B. Diabetes mellitus: diabetic gastroparesis (DG) 29%.

- TIDM has worse clinical presentation
- Requires diabetic neuropathy.

C. Post surgical (13%)

- Gastric resection with vagal nerve injury.
- Fundoplication or bariatric surgery that involves gastroplasty or bypass procedures.

D. Medications:

- > Opiates, TCAs, CCBs, dopamine agonists, progesterone and clonidine.
- The antirejection drug as cyclosporine and Tacrolimus .

E. Neurological:

• Parkinson's disease, multiple sclerosis.

F. Rheumatological:

- ➢ Scleroderma: deposition of collagen.
- > Amyloidosis: deposition of amyloid protein.

G. Viral infection

□Viruses such as cytomegalovirus, Epstein–Barr virus, and varicella zoster may develop a form of autonomic neuropathy (generalized or selective cholinergic dysautonomia) that includes gastroparesis.

H- Other causes Spinal trauma, Mesenteric ischemia, Hypothyroidism.



- I. Rule out mechanical obstruction:
- Imaging(CT scan , barium).
- Upper endoscopy.

2. Detect delayed gastric emptying:

- Scintigraphy.
- Wireless motility capsule (WMC).
- Breath testing.

Rules for gastric emptying tests:

- Stop medications that affect gastric emptying for 48–72 h.
- Relative euglycemia (blood glucose <200 mg/dl) is achieved in diabetics to obtain a reliable parameters.</p>

1-Scintigraphy

- The gold standard test for measurement of gastric emptying.
- A solid-phase meal is considered as the standard "sulfur colloid-labeled egg sandwich".
- Standard imaging at 0, 1, 2, and 4 h.
- Measurement of liquid gastric emptying in addition to solid emptying, has been advocated as a means of increasing sensitivity

Prior to test :

- Stop medication delay gastric emptying 48 72hrs.
- Maintain good blood glucose < 200 mg/dl.</p>

Positive if:

- >60% of gastric content remain after 2hrs.
- >10% after 4hrs.
- I0-15% mild15-35% moderate.....>35% sever.

2-Wireless Motility Capsule (WMC)

- The principle of this test is based on the precipitous rise in pH as the capsule empties from the acidic gastric lumen into the bicarbonate-rich duodenum.
- Gastric emptying is determined when there is a rapid increase in the pH recorded indicating emptying from the acidic stomach to the alkaline duodenum.
- Correlation between gastric emptying time of the WMC and gastric emptying at 4 h by scintigraphy should be done.


3-Breath testing


- Based on the principle that the rate of gastric emptying of I3C substrate incorpo- rated in the solid test meal is reflected by breath excretion of I3CO2.
- premeal breath samples are collected after an 8-hour fast, followed by additional samples collected over 4 hours after eating the test meal.
- GEBT can be safely used in pregnant , breast- feeding women and in children.
- Both WMC and breath testing require further validation before they can be considered as alternates to scintigraphy for diagnosis of gastroparesis.



 \geq Rumination syndrome.

- Cyclic vomiting syndrome .
- Cannabinoid hyperemesis.





Cyclic vomiting syndrome:

- Recurrent episodes of nausea and vomiting lasting hours to days separated by symptom-free periods of variable lengths.
- Each episode is similar.
- Vomiting often starts abruptly, although a prodrome of nausea and abdominal pain can occur.
- Typically, gastric emptying in CVS is normal or rapid; however, 14% of a large series of patients had delayed gastric emptying

Management.

- i. CONSERVATIVE
- ii. PHARMACOLOGICAL
- iii. INTRAPYLORIC BOTULINUM TOXIN INJECTION
- iv. GASTRIC ELECTRICAL STIMULATION
- v. SURGICAL

I-Conservative:

A- Maintaining oral nutrition is the goal of therapy.

B-Dietary modification:

- The initial step of dietary modification involves cooking non digestible fiber and mechanically homogenizing solids to a small particle size.
- Avoid insoluble fibers, alcohol, smoking.
- Iow-fat and fiber content.
- Small meal size is advisable 4–5 times a day.
- Increasing the liquid nutrient .
- Maintain good hydration and electrolyte balance.

C-Glycemic control

D-Enteral Nutrition

- In severe gastroparesis, enteral or parenteral nutrition may be needed.
- Enteral feeding preferred over parenteral nutrition for many reasons as costs, complications and ease of delivery.
- Trial of naso-jejunal feeding should be done if failed feeding jejunostomy tube is indicated.
- Small intestinal motility can be assessed before placement of jejunostomy tube with manometry, WMC, and small intestinal scintigraphy.

Complications

- Infection, thrombosis
- Tube migration.
- Dislodgement .

Pharmacological:

A. Prokinetic agents:

Are the first-line therapy for treatment of gastroparesis. they enhance gastric emptying and reduce gastroparesis symptoms


I- Metoclopramide:

- Central and peripheral dopamine receptor antagonist.
- available in liquid oral, nasal spray, and parenteral (IV or subcutaneous) formulations
- liquid formulation is preferred, 5-10 mg 3 times per day, 15 minutes before meals.

- Not used more than 12 wks with 10-day interruptions every 3 months.
- During the drug holidays, patients are instructed to adhere strictly to a liquid diet.

The most common side effects occur because metoclopramide crosses the blood-brain barrier causing extrapyramidal symptoms as anxiety, agitation, somnolence dystonia.

- parkinsonism.
- dyskinesia .
- QT interval prolongation.



3. Macrolides

- Macrolides such as erythromycin, azithromycin, and clarithromycin are motilin receptor agonists with a prokinetic property.
- They accelerate gastric emptying and improved symptoms.
- When given orally > 4 weeks it associated with tolerance and with QT prolongation.
- In hospitalized patients, IV erythromycin (infused over 45 minutes) at 1.5 mg/kg to 3.0 mg/kg 3 times per day.
- Long-term use of antibiotics may be associated with complications including antibiotic resistance and potential infections such as Clostridioides difficile toxin— induced colitis or antibiotic-induced diarrhea.

4-5-HT4 receptor agonists as :-

- cisapride was efficacious but it was withdrawn because of increased risk of cardiac arrhythmias.
- Prucalopride is approved for the treatment of chronic constipation, but not for gastroparesis.

B.Anti emetic	
Antiemetics acting o mg every 8 hours	n different mechanisms have been used at Dosed of 4 mg to 8
> ondansetron is a 5-h	ydroxytryptamine 3 receptor antagonist
Prochlorperazine	
promethazine	
> and scopolamine	
The synthetic cannal withdrawal.	binoid, is also used, but there is risk of hyperemesis on
The neurokinin-1 re- induced emesis)	ceptor antagonist aprepitant (approved for chemotherapy-

C-Analgesic

>Narcotic opiate analgesics should be stopped.

Neuromodulators such as amitriptyline and nortriptyline are often considered first-line treatment for functional abdominal pain

>Tramadol, gabapentin, pregabalin, may be alternatives for pain.

Pyloric Interventions

- Manometric studies of patients with DG show increased pyloric tone and contractions, a phenomenon termed as "pylorospasm."
- interventions directed at the pylorus, including botulinum toxin injection, pyloric dilation and/or stenting, and surgical or endoscopic pyloromyotomy.
- Botulinum toxin is a potent inhibitor of neuromuscular transmission.
- repeated injection with high-dose botulinum toxin may induce pyloric fibrosis over time, thus reducing the feasibility of future intervtions such as pyloromyotomy.

Gastric peroral endoscopic myotomy (G-POEM)

- Is a novel pyloric intervention that has become increasingly popular as a promising treatment for refractory gastropa- resis.
- Accessing the pyloric muscle from the gastric luminal side with an endoscopy, G-POEM cuts predominantly the circular muscle layer while leaving the longitudinal muscle intact to avoid perforation.

Gastric Electirical Stimulation (GES)

- By using high-frequency electrical pulses delivered to the smooth muscles of the stomach, aims to modulate the afferent pathway and reduce gastroparesis symptoms in patients with refractory gastroparesis.
- GES improve vomiting but not gastric emptying or quality-of-life.
- Another novel experimental devices have been developed to activate the antral muscles by directly stimulating the efferent vagal fibers or by centrally stimulating the afferent vagus nerve.
- It is non invasive self-administered stimulation devices applied to the vagus nerve in the neck.

Medications in developement

- Relamorelin (Allergan) is a penta- peptide ghrelin receptor agonist with evidence of strong prokinetic potency.
- Trazpiroben (Takeda) is a dopamine D2/D3 receptor antagonist with minimal brain penetration. It improve postprandial symptoms in patients with idiopathic or diabetic gastroparesis

Alternative Therapy

 Acupuncture is one of the most well-studied Eastern medicine therapies but further studies are needed to assess its clinical benefit.

SURGICAL TREATMENTS

- VENTING GASTROSTOMY.
- GASTROJEUNOSTOMY.
- PYLOROPLASTY.
- GASTRECTOMY.
- Complete or subtotal gastrectomy was applied most often for gastroparesis that followed gastric surgery for peptic ulcer disease.
- In carefully selected patients, major gastric surgery can relieve distressing vomiting from severe gastroparesis and improve quality of life.
- The risk of malnutrition and weight loss following gastrectomy has to be weighed relative to the symptom relief.
- Subtotal gastrectomy with Roux-Y reconstruction may be needed for gastric atony secondary to PSG.

Suspected gastroparesis

Step 1: Diagnosis: 4 h Gastric emptying by scintigraphy

Step 2: Exclude iatrogenic disease Dietary: low fat, low fiber diet Glycemic control among diabetics

Step 3: Pharmacological Rx:

Prokinetics: metoclopramide, erythromycin, domperidone

Antiemetics: anti-histamine, receptors; 5-HT₃ antagonists

Step 4: Nutritional support: Enternal formula

Step 5: Non-pharmacological Rx Pyloric injection of botulinum toxin Venting gastrostomy, feeding jejunostomy Parenteral nutrition Gastric electrical stimulation Pyloroplasty Partial gastrectomy

